Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.

Maria FrånlundMarianne MånssonRebecka Arnsrud GodtmanGunnar AusErik HolmbergKarin Stinesen KollbergPär LoddingCarl-Gustaf PihlJohan StranneHans LiljaJonas Hugosson

Published in: The Journal of urology (2022)

Prostate specific antigen-based screening substantially decreases PC mortality. However, not attending, starting after age 60 and stopping at age 70 seem to be major pitfalls regarding PC death risk.

Keyphrases

prostate cancer
phase iii
phase ii
open label
double blind
clinical trial
radical prostatectomy
study protocol
placebo controlled
risk factors